The solution also includes qualitative and quantitative tools to validate the accuracy of deformable image registration, helping ensure that doses from prior treatments are correctly mapped onto current patient anatomy. This capability is particularly important in gynecologic cases, where anatomical variations – such as those caused by HDR applicators – can complicate treatment planning.
“MIM ComboTherapy™ GYN HDR/EBRT represents an important step forward in helping clinicians confidently plan complex combination therapies,” says J Anders, General Manager, MIM, GE HealthCare. “By providing a clearer understanding of the total radiation dose a patient receives across treatments, this solution helps clinicians make more informed decisions. As cancer care continues to move toward more personalized, data-driven approaches, innovations like this can play an important role in helping improve treatment planning and outcomes for women undergoing radiation therapy.”
Ad Statistics
Times Displayed: 4950
Times Visited: 14 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
Early clinical evaluations suggest that advanced deformable registration and spatial dose mapping approaches – like those supported by MIM – can provide a clinically viable framework for assessing dose accumulation in gynecologic combination therapy, enabling greater confidence in treatment planning decisions.
The technology is part of the MIM Software portfolio within GE HealthCare’s radiation oncology ecosystem and is designed to integrate seamlessly into existing clinical workflows. With standardized processes, automation, and vendor-neutral compatibility across treatment planning systems, MIM ComboTherapy™ helps streamline plan preparation while maintaining flexibility for diverse clinical environments.
Back to HCB News
